pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,762 catalysts · 4,686 phase readout · 2,347 8k filing · 285 earnings · 201 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,686
  • 8k filing2,347
  • earnings285
  • pdufa201
  • phase 2 completion172
  • phase 1 completion73
  • phase 2 initiation62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 30, 2026phase 2 completion84d agoCarlo Bo University of Urbino — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Gastrointestinal. Indication: Diarrhea

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoHuzhou Maternity and Child Care Hospital — esketamine (Phase II Trial Completion)esketamine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain, Sleep Disorders

    full page →esketamine →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoJetema Co Ltd — JTM-102 (Phase II Trial Completion)JTM-102

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →JTM-102 →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoUniversity of Udine — cholecalciferol (Phase II Trial Completion)cholecalciferol

    Therapy area: Musculoskeletal Disorders. Indication: Sarcopenia

    full page →cholecalciferol →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoShionogi & Co Ltd — daridorexant hydrochloride (Phase II Trial Completion)daridorexant hydrochloride

    Therapy area: Central Nervous System. Indication: Insomnia

    full page →daridorexant hydrochloride →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoFirst Affiliated Hospital of Kunming Medical University — sugammadex (Phase II Trial Completion)sugammadex

    Therapy area: Non Malignant Disorders, Women's Health. Indication: Unspecified Gynecological Disorders, Uterine Leiomyoma (Uterine Fibroids)

    full page →sugammadex →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoInstitute of Liver and Biliary Sciences — darbepoetin alfa (Phase II Trial Completion)darbepoetin alfa

    Therapy area: Gastrointestinal. Indication: Decompensated Cirrhosis, Liver Cirrhosis

    full page →darbepoetin alfa →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

    Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

    full page →amoxicillin →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoAristotle University of Thessaloniki — oleocanthal (Phase II Trial Completion)oleocanthal

    Therapy area: Central Nervous System. Indication: Mild Cognitive Impairment

    full page →oleocanthal →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoBiogen Inc — DNL-151 (Phase II Trial Completion)DNL-151

    Therapy area: Central Nervous System. Indication: Parkinson's Disease

    full page →DNL-151 →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoAffiliated Stomatological Hospital of Guangxi Medical University — autologous platelet rich plasma (Phase II Trial Completion)autologous platelet rich plasma

    Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Arthralgia (Joint Pain), Osteoarthritis

    full page →autologous platelet rich plasma →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoVertex Pharmaceuticals Inc — VX-993 (Phase II Trial Completion)VX-993

    Therapy area: Central Nervous System. Indication: Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain

    full page →VX-993 →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoChinese Academy of Medical Sciences Plastic Surgery Hospital — recombinant type III humanized collagen (Phase II Trial Completion)recombinant type III humanized collagen

    Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)

    full page →recombinant type III humanized collagen →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoChinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)fuzuloparib

    Therapy area: Oncology. Indication: Soft Tissue Sarcoma

    full page →fuzuloparib →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoSun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)ISOTRETINOIN

    Therapy area: Oncology. Indication: Neuroblastoma

    full page →ISOTRETINOIN →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

    full page →ghrelin →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoFundacion para la Investigacion Biomedica Hospital Clinico San Carlos — cromolyn sodium (Phase II Trial Completion)Gastrocrom

    Therapy area: Central Nervous System. Indication: Multiple Sclerosis

    full page →Gastrocrom →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoGachon University Gil Medical Center — Wegovy (Phase II Trial Completion)Wegovy Pill

    Therapy area: Metabolic Disorders. Indication: Obesity

    full page →Wegovy Pill →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoWannan Medical College First Affiliated Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Undisclosed. Indication: Unspecified

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoWestern New England University — grape powder (Phase II Trial Completion)grape powder

    Therapy area: Central Nervous System. Indication: Cognitive Disorders

    full page →grape powder →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoKLE College of Pharmacy, Belagavi — undisclosed immunosuppressive drug (Phase II Trial Completion)undisclosed immunosuppressive drug

    Therapy area: Genito Urinary System. Indication: Nephrotic Syndrome

    full page →undisclosed immunosuppressive drug →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoUniversity of Minnesota — Lactobacillus casei (Phase II Trial Completion)Lactobacillus casei

    Therapy area: Musculoskeletal Disorders. Indication: Muscle Injury, Unspecified Musculoskeletal Disorders

    full page →Lactobacillus casei →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoArrae Inc — Aframomum melegueta extract (Phase II Trial Completion)Aframomum melegueta extract

    Therapy area: Metabolic Disorders. Indication: Obesity, Overweight

    full page →Aframomum melegueta extract →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

    Therapy area: Immunology. Indication: Inflammation

    full page →SSJG-009 →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoCharak Ayurvedic Pharmacy, Paprola — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Metabolic Disorders, Musculoskeletal Disorders. Indication: Hyperuricemia, Unspecified Musculoskeletal Disorders

    full page →ayurvedic medicine →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoBuddhachinaraj Hospital — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Musculoskeletal Disorders. Indication: Bone Fracture

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

    Therapy area: Respiratory. Indication: Cough

    full page →LIDOCAINE →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoChongqing Medical University Hospital 2 — propofol (Phase II Trial Completion)PROPOFOL

    Therapy area: Central Nervous System. Indication: Cognitive Disorders

    full page →PROPOFOL →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoHematology Hospital of Chinese Academy of Medical Sciences — letermovir (Phase II Trial Completion)letermovir

    Therapy area: Undisclosed. Indication: Unspecified

    full page →letermovir →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoCantonal Hospital Authority — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

    full page →Vacucis →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)atezolizumab

    Therapy area: Oncology. Indication: Prostate Cancer

    full page →atezolizumab →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoNoster Inc — 10-hydroxy-cis-12- octadecenoic acid (Phase II Trial Completion)10-hydroxy-cis-12- octadecenoic acid

    Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

    full page →10-hydroxy-cis-12- octadecenoic acid →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoHospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)adebrelimab

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

    full page →adebrelimab →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)capecitabine

    Therapy area: Oncology. Indication: Colorectal Cancer

    full page →capecitabine →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoNanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)adebrelimab

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →adebrelimab →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoLifeArc — fecal microbiota (Phase II Trial Completion)fecal microbiota

    Therapy area: Gastrointestinal. Indication: Inflammatory Bowel Disease, Primary Sclerosing Cholangitis

    full page →fecal microbiota →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoNational Cheng-Kung University Hospital — SynPro-15G (Phase II Trial Completion)SynPro-15G

    Therapy area: Gastrointestinal. Indication: Irritable Bowel Syndrome

    full page →SynPro-15G →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoPolice General Hospital — acetaminophen (Phase II Trial Completion)acetaminophen ER

    Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 2 completion84d agoEmory University — (carbidopa + levodopa) (Phase II Trial Completion)(carbidopa + levodopa)

    Therapy area: Central Nervous System. Indication: Cognitive Disorders, Depression

    full page →(carbidopa + levodopa) →source: globaldata
    ›Apr 30, 20268k filing84d ago$HCWB — HCW Biologics Inc. (HCWB) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing84d ago$BCYC — BICYCLE THERAPEUTICS PLC (BCYC) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing84d ago$RNAC — Cartesian Therapeutics, Inc. (RNAC) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing84d ago$QURE — uniQure N.V. (QURE) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing84d ago$KYMR — Kymera Therapeutics, Inc. (KYMR) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing84d ago$LLY — ELI LILLY & Co (LLY) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing84d ago$NVCR — NovoCure Ltd (NVCR) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing84d agoBRISTOL MYERS SQUIBB CO (BMY, CELG-RI) — 8-K filing

    Items: 2.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing84d ago$PYXS — Pyxis Oncology, Inc. (PYXS) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing84d ago$PHAT — Phathom Pharmaceuticals, Inc. (PHAT) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ← prev
    page 14 of 156
    next →
    $VERX12.28-4.73%
    $BIIB203.16+1.61%
    $SGIOF17.550.00%
    $RCUS29.24-0.81%